guest ::
| Home > Publications Database > The smoking paradox in ischemic stroke patients treated with intra-arterial thrombolysis in combination with mechanical thrombectomy-VISTA-Endovascular. > print |
| Home > Publications Database > The smoking paradox in ischemic stroke patients treated with intra-arterial thrombolysis in combination with mechanical thrombectomy-VISTA-Endovascular. > print |
| 001 | 155122 | ||
| 005 | 20240411115844.0 | ||
| 024 | 7 | _ | |a 10.1371/journal.pone.0251888 |2 doi |
| 024 | 7 | _ | |a pmid:34014988 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC8136663 |2 pmc |
| 024 | 7 | _ | |a altmetric:106660460 |2 altmetric |
| 037 | _ | _ | |a DZNE-2021-00443 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Kufner, Anna |0 P:(DE-HGF)0 |b 0 |
| 245 | _ | _ | |a The smoking paradox in ischemic stroke patients treated with intra-arterial thrombolysis in combination with mechanical thrombectomy-VISTA-Endovascular. |
| 260 | _ | _ | |a San Francisco, California, US |c 2021 |b PLOS |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1712749127_11352 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a The smoking-paradox of a better outcome in ischemic stroke patients who smoke may be due to increased efficacy of thrombolysis. We investigated the effect of smoking on outcome following endovascular therapy (EVT) with mechanical thrombectomy alone versus in combination with intra-arterial (IA-) thrombolysis.The primary endpoint was defined by three-month modified Rankin Scale (mRS). We performed a generalized linear model and reported relative risks (RR) for smoking (adjustment for age, sex, hypertension, atrial fibrillation, stroke severity, time to EVT) in patient data stemming from the Virtual International Stroke Trials Archive-Endovascular database.Among 1,497 patients, 740(49.4%) were randomized to EVT; among EVT patients, 524(35.0%) received mechanical thrombectomy alone and 216(14.4%) received it in combination with IA-thrombolysis. Smokers (N = 396) had lower mRS scores (mean 2.9 vs. 3.2; p = 0.02) and mortality rates (10% vs. 17.3%; p<0.001) in univariate analysis. In all patients and in patients treated with mechanical thrombectomy alone, smoking had no effect on outcome in regression analyses. In patients who received IA-thrombolysis (N = 216;14%), smoking had an adjusted RR of 1.65 for an mRS≤1 (95%CI 0.77-3.55). Treatment with IA-thrombolysis itself led to reduced RR for favorable outcome (adjusted RR 0.30); interaction analysis of IA-thrombolysis and smoking revealed that non-smokers with IA-thrombolysis had mRS≤2 in 47 cases (30%, adjusted RR 0.53 [0.41-0.69]) while smokers with IA-thrombolysis had mRS≤2 in 23 cases (38%, adjusted RR 0.61 [0.42-0.87]).Smokers had no clear clinical benefit from EVT that incorporates IA-thrombolysis. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 2 | |a Aged |2 MeSH |
| 650 | _ | 2 | |a Atrial Fibrillation: complications |2 MeSH |
| 650 | _ | 2 | |a Atrial Fibrillation: physiopathology |2 MeSH |
| 650 | _ | 2 | |a Endovascular Procedures: methods |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Hypertension: complications |2 MeSH |
| 650 | _ | 2 | |a Hypertension: physiopathology |2 MeSH |
| 650 | _ | 2 | |a Ischemic Stroke: physiopathology |2 MeSH |
| 650 | _ | 2 | |a Ischemic Stroke: rehabilitation |2 MeSH |
| 650 | _ | 2 | |a Ischemic Stroke: therapy |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Mechanical Thrombolysis: methods |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Smoking: adverse effects |2 MeSH |
| 650 | _ | 2 | |a Smoking: physiopathology |2 MeSH |
| 650 | _ | 2 | |a Thrombectomy: adverse effects |2 MeSH |
| 650 | _ | 2 | |a Thrombolytic Therapy: methods |2 MeSH |
| 650 | _ | 2 | |a Tobacco Smoking: adverse effects |2 MeSH |
| 650 | _ | 2 | |a Treatment Outcome |2 MeSH |
| 700 | 1 | _ | |a Ali, Huma Fatima |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Ebinger, Martin |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Fiebach, Jochen B |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Liebeskind, David S |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Endres, Matthias |0 P:(DE-2719)2811033 |b 5 |
| 700 | 1 | _ | |a Siegerink, Bob |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a VISTA-Endovascular Collaborators |0 P:(DE-HGF)0 |b 7 |e Collaboration Author |
| 773 | _ | _ | |a 10.1371/journal.pone.0251888 |g Vol. 16, no. 5, p. e0251888 - |0 PERI:(DE-600)2267670-3 |n 5 |p e0251888 |t PLOS ONE |v 16 |y 2021 |x 1932-6203 |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/155122/files/DZNE-2021-00443.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/155122/files/DZNE-2021-00443.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:155122 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 5 |6 P:(DE-2719)2811033 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 913 | 0 | _ | |a DE-HGF |b Gesundheit |l Erkrankungen des Nervensystems |1 G:(DE-HGF)POF3-340 |0 G:(DE-HGF)POF3-344 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-16 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1040 |2 StatID |b Zoological Record |d 2022-11-16 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b PLOS ONE : 2021 |d 2022-11-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2022-04-12T10:14:32Z |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2022-04-12T10:14:32Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-16 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-16 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2022-11-16 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-16 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-02-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-16 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2021-02-04 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-2719)1811005 |k AG Endres |l Interdisciplinary Dementia Research |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1811005 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|